FASENRA (AstraZeneca Pty Ltd)
Product name
FASENRA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
211 (255 working days)
Active ingredients
benralizumab
Registration type
EOI
Indication
Relapsed or refractory Eosinophilic granulomatosis with polyangiitis (EGPA)
FASENRA is indicated as an add-on treatment for relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over (see Section 5.1 Pharmacodynamic properties [Clinical Trials]).